What is Jude Bio?
Jude Bio is a biotechnology innovator specializing in the development of oligonucleotide medicines specifically engineered for delivery to the kidney. At the core of its operations is the STRIKE (Selectively Targeting RNA Into KidnEy) platform, a proprietary technology that leverages natural, endogenous mechanisms to ensure precise therapeutic delivery. By utilizing ligand-siRNA conjugate drugs, the company facilitates receptor-mediated uptake in specific kidney cell types, effectively silencing disease-modifying genes. This approach positions Jude Bio at the forefront of RNA medicine, offering a novel pathway to treat both systemic and renal-specific pathologies that have historically been difficult to address with conventional pharmacological interventions.
How much funding has Jude Bio raised?
Jude Bio has raised a total of $100M across 1 funding round:
Angel/Seed
$100M
Angel/Seed (2024): $100M with participation from The Column Group, TCG, and Atlas Venture
Key Investors in Jude Bio
The Column Group
The Column Group is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, known for its edge-to-edge investment model that supports biotech companies from inception to exit.
TCG
TCG Inc delivers specialized information technology and management advisory services to federal government agencies, with a strong focus on health science analytics and complex mission-critical operations.
Atlas Venture
Atlas Venture is a pioneering early-stage venture capital firm dedicated to building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines.
What's next for Jude Bio?
With this recent financing, Jude Bio is well-positioned to transition its initial drug programs from the laboratory to more advanced stages of development. The strategic focus will likely center on scaling the STRIKE platform to validate its efficacy in broader clinical applications. As the company matures, the emphasis will shift toward optimizing its gene-silencing capabilities and establishing partnerships that can facilitate the commercialization of its pipeline. Investors are closely monitoring the firm's ability to translate its unique targeting mechanism into tangible patient outcomes, which will be critical for future growth and potential exit opportunities in the competitive biotech landscape.
See full Jude Bio company page
